((2S,5R)-5-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2,5-dihydrofuran-2-yl)methyl benzoate – (122567-97-9)

nevirapine, 129618-40-2, Viramune, BI-RG-587, Nevirapine anhydrous, 11-Cyclopropyl-4-methyl-5, 11-dihydro-6H-dipyrido[3, 2-b:2', 3'-e][1, 4]diazepin-6-one, NVP, Viramune XR, BIRG 0587, BIRG587, Nevirapine, anhydrous, Nevirapine teva, 11-Cyclopropyl-5, 11-dihydro-4-methyl-6H-dipyrido(3, 2-b:2', 3'-e)(1, 4)diazepin-6-one, BIRG-0587, Viramune (TN), 11-CYCLOPROPYL-5, 11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3, 2-B:2', 3'-E][1, 4]DIAZEPIN-6-ONE, Nevirapina, BIRG-587, BI-RG 587, HSDB 7164, 99DK7FVK1H, MFCD00866928, Nevirapinum anhydrous, NSC 641530, NSC-641530, DTXSID7031797, CHEBI:63613, Nevirapine [USAN:USP:INN:BAN], NEVIRAPINE [MI], CHEMBL57, NEVIRAPINE [INN], NEVIRAPINE [JAN], 11-Cyclopropyl-4-methyl-5, 11-dihydro-6H-dipyrido[2, 3-e:3', 2'-b][1, 4]diazepin-6-one, 6H-Dipyrido(3, 2-b:2', 3'-e)(1, 4)diazepin-6-one, 11-cyclopropyl-5, 11-dihydro-4-methyl-, NEVIRAPINE [HSDB], NEVIRAPINE [USAN], NSC641530, NEV, NEVIRAPINE [VANDF], NEVIRAPINE [MART.], NEVIRAPINE [WHO-DD], BI RG 587, NEVIRAPINE [EMA EPAR], 11-CYCLOPROPYL-4-METHYL-5H-DIPYRIDO[3, 2-B:2', 3'-E][1, 4]DIAZEPIN-6(11H)-ONE, MLS000084585, DTXCID9010787, NEVIRAPINE [ORANGE BOOK], NEVIRAPINE [EP MONOGRAPH], NEVIRAPINE [USP IMPURITY], NEVIRAPINE [USP MONOGRAPH], NEVIRAPINE ANHYDROUS [USP-RS], NEVIRAPINE ANHYDROUS [WHO-IP], 2-cyclopropyl-7-methyl-2, 4, 9, 15-tetrazatricyclo[9.4.0.03, 8]pentadeca-1(11), 3, 5, 7, 12, 14-hexaen-10-one, NCGC00065890-02, SMR000048458, NEVIRAPINUM ANHYDROUS [WHO-IP LATIN], NEVIRAPINE (MART.), NEVIRAPINE (EP MONOGRAPH), NEVIRAPINE (USP IMPURITY), NEVIRAPINE (USP MONOGRAPH), Nevirapine (USAN:USP:INN:BAN), NEVIRAPINE ANHYDROUS (USP-RS), Viramune(TM), 2-cyclopropyl-7-methyl-2, 4, 9, 15-tetraazatricyclo[9.4.0.0^{3, 8}]pentadeca-1(11), 3, 5, 7, 12, 14-hexaen-10-one, 2-cyclopropyl-7-methyl-2, 4, 9, 15-tetraazatricyclo[9.4.0.0^{3, 8}]pentadeca-1(15), 3, 5, 7, 11, 13-hexaen-10-one, CAS-129618-40-2, Nevirapine & CD4-IgG, Nevirapine & PRO 140, UNII-99DK7FVK1H, nevirapinum, Nevirapine (JAN/USP/INN), Nevirapine), 11-cyclopropyl-4-methyl-5H-dipyrido[[?], [?]][1, 4]diazepin-6-one, BIRG 587, NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE, Viramune IR, 1vrt, 2hny, 11-cyclopropyl-4-methyl-5, 11-dihydro-6H-dipyrido(3, 2-b:2', 3'-e)(1, 4)diazepin-6-one, BI-RG-587 & CD4-IgG, 2-cyclopropyl-7-methyl-2, 4, 9, 15-tetraazatricyclo(9.4.0.0^(3, 8))pentadeca-1(15), 3, 5, 7, 11, 13-hexaen-10-one, 2-cyclopropyl-7-methyl-2, 4, 9, 15-tetrazatricyclo(9.4.0.03, 8)pentadeca-1(11), 3, 5, 7, 12, 14-hexaen-10-one, 6H-DIPYRIDO[3, 2-B:2', 3'-E][1, 4]DIAZEPIN-6-ONE, 11-CYCLOPROPYL-5, 11-DIHYDRO-4-METHYL-, Nevirapine (Standard), Nevirapine (Viramune), Nevirapine (anhydrous), Opera_ID_934, SCHEMBL3318, MLS000759409, MLS001055309, MLS001201730, MLS001424058, MLS006011423, BIDD:GT0326, BDBM1434, BIRG0587, GTPL12676, J05AG01, Nevirapine for peak identification, HMS2051J09, HMS2231O23, HMS3264D21, HMS3371E03, HMS3393J09, HMS3655I08, HMS3715B10, Pharmakon1600-01503842, ALBB-027264, BCP05587, BSB41895, Tox21 110982, Tox21_110982, Tox21_200770, AC-643, AC1280, BBL010768, HY-10570R, NSC759902, STK580320, AKOS005504351, Tox21_110982_1, AB07544, CCG-100939, DB00238, KS-5019, NC00189, NN15304, NSC-759902, NCGC00065890-03, NCGC00065890-04, NCGC00065890-05, NCGC00065890-07, NCGC00065890-14, NCGC00258324-01, 11-Cyclopropyl-4-methyl-5, 11-dihydro-6H-dipyrido[2, 3-e:3', 2'-b][1, 4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody), HY-10570, N11-Cyclopropyl-4-methyl-5, 11-dihydro-6H-dipyrido[3, 2-b:2', 3'-e]-[1, 4]diazepin-6-one & CD4-immunoadhesin, Nevirapine 100 microg/mL in Acetonitrile, SY009679, BI-RG 587 NSC 641530 NVP, DB-041930, N0922, NEVIRAPINE TABLETS FOR ORAL SUSPENSION, NS00004959, S1742, SW197569-2, C07263, D00435, EN300-119500, AB00393001-13, AB00393001-15, AB00393001_16, AB00393001_17, Q263713, BRD-K15502390-001-19-1, BRD-K15502390-001-20-9, F2173-0607, Z1521553473, BI-RG-587 BIRG 0587 BIRG587 HSDB 7164 NSC 641530 NVP, Nevirapine (anhydrous), European Pharmacopoeia (EP) Reference Standard, Nevirapine anhydrous, United States Pharmacopeia (USP) Reference Standard, Nevirapine, Pharmaceutical Secondary Standard Certified Reference Material, 11-cyclopropyl-5, 11-dihydro-4-methyl-6H-dipyrido-[3, 2-b:2', 3'-e][1, 4]diazepin-6-one, 11-cyclopropyl-5, 11-dihydro-4-methyl-6H-dipyrido[3, 2-b :2', 3'-e][1, 4 ]diazepin-6-one, 11-cyclopropyl-5, 11-dihydro-4-methyl-6H-dipyrido[3, 2-b:2, 3 -e][1, 4]diazepin-6-one, 11-Cyclopropyl-5, 11-dihydro-4-methyl-6H-dipyrido[3, 2-b:2', 3'-e][1, 4]diazepin-6-one, 6H-dipyrido[2, 3-e:3', 2'-b][1, 4]diazepin-6-one, 11-cyclopropyl-5, 11-dihydro-4-methyl-, Nevirapine for peak identification, European Pharmacopoeia (EP) Reference Standard, 11-Cyclopropyl-4-methyl-5, 11-dihydro-6H-dipyrido[3, 2-b:2 inverted exclamation mark, 3 inverted exclamation mark -e][1, 4]diazepin-6-one, 2-cyclopropyl-7-methyl-2, 4, 9, 15-tetraazatricyclo[9.4.0.0, 3, 8]pentadeca-1(15), 3(8), 4, 6, 11, 13-hexaen-10-one, 603-345-0